DoD Prostate Cancer, Translational Science Award | W81XWH 21 PCRP TSA

Opportunity Information: Apply for W81XWH 21 PCRP TSA

The DoD Prostate Cancer Research Program (PCRP) Translational Science Award (TSA) is a FY21 funding opportunity designed to push mature, well-supported prostate cancer discoveries closer to real-world clinical use. The program is centered on advanced translational research, meaning projects must deliberately connect basic science with clinical observations and needs, with a clear emphasis on moving beyond early discovery. The end goal is practical: convert promising ideas into clinical applications that can address one or more of the FY21 PCRP Overarching Challenges. The opportunity treats translation as a two-way street, encouraging projects where clinical observations inform lab work (bedside to bench) as well as lab findings guiding clinical direction (bench to bedside).

The TSA is meant for later-stage translational efforts rather than first-pass target discovery or purely mechanistic exploration. Examples of the types of projects the DoD expects include advanced preclinical studies that build on prior animal work and move toward validation in human samples or patient cohorts; late-stage preclinical development that prepares for a future clinical trial (including work that supports an Investigational New Drug, or IND, submission); correlative studies tied to open, ongoing, or completed clinical trials, especially those that use trial biospecimens to refine clinical management or open new translational directions; and projects aimed at developing or refining clinical trial endpoints. A key point is that clinical trials themselves are not allowed under this mechanism, even though human subjects research can be included. The sweet spot is research that directly strengthens the evidence base and readiness for the next clinical step, without being the interventional trial step.

A strong application is expected to be data-driven from the start. Preliminary data are required to justify both the scientific rationale and the feasibility of the proposed approach, and applicants are strongly encouraged to provide additional preliminary evidence that the idea is clinically relevant. The DoD also places visible weight on statistical rigor and study design. Applicants are expected to justify sample sizes carefully, show that they can access the needed cohorts, biospecimens, or other resources, and explain why the planned numbers and analyses will support valid conclusions. For animal and other preclinical work, the announcement points applicants toward widely recognized rigor and reproducibility standards, including principles like randomization, blinding, sample-size estimation, and transparent data handling, as well as the ARRIVE guidelines and related reporting expectations.

Because the program is explicitly translational, every proposal must include a detailed transition plan. This is more than a general statement of future interest; it should map the path for what happens after the award ends, explaining how successful outcomes will be advanced into the next phase of development and how the research team will keep pushing toward clinical impact, even if the project itself will not deliver immediate changes in patient care during the award period. This transition plan functions like a roadmap for practical adoption: what gets validated next, what regulatory or operational steps might follow, and how the work positions the field for a subsequent clinical study or implementation effort.

The opportunity also encourages team science through an optional Partnering PI structure. Applications may name two PIs who bring distinct, complementary contributions, ideally bridging basic and clinical expertise. One PI serves as the Initiating PI and handles most submission and administrative responsibilities, while the Partnering PI plays a substantial scientific role in shaping the narrative, statement of work, and other core application elements. If selected, each PI is associated with an individual award within the recipient organization, reflecting the program’s intent for real collaboration rather than nominal co-investigator arrangements.

From an administrative and compliance standpoint, awards are made as assistance agreements, which can be either grants or cooperative agreements. Whether the award is a grant or a cooperative agreement depends on how much substantial involvement the DoD anticipates during performance. If the agency expects to collaborate, participate, or otherwise be actively involved beyond normal oversight, the mechanism may shift toward a cooperative agreement; if not, it is more likely to be a standard grant. The final structure and start date are determined during negotiation.

The DoD emphasizes relevance to Service Members, Veterans, military beneficiaries, and the broader American public. Proposals should make that relevance explicit, and the program strongly encourages collaborations between military or Veteran institutions and non-military organizations, leveraging unique patient populations, clinical infrastructure, and complementary expertise. The announcement also points applicants to recommendations from the congressionally mandated Metastatic Cancer Task Force and encourages ideas aligned with those recommendations, as long as they fit within the TSA’s limits and FY21 PCRP priorities, particularly for efforts aimed at improving outcomes for advanced-stage and recurrent disease.

Funding-wise, the anticipated direct costs for the entire period of performance are capped at $750,000. The DoD projected a total allocation of about $7.2 million to fund roughly six awards. Awards were expected to be made no later than September 30, 2022, and the FY21 funds associated with resulting awards were anticipated to remain available for use until September 30, 2027, reflecting the limited period in which those appropriated funds can be obligated and expended.

Finally, the announcement lays out important oversight requirements for studies involving people, specimens, animals, or certain sensitive resources. Human subjects research and research involving human anatomical substances or cadavers must receive review and approval not only from a local IRB or ethics body, but also from the USAMRDC Office of Research Protections, Human Research Protection Office (HRPO), before the work can begin; applicants are told to plan for an additional 2 to 3 months for this regulatory review. Multi-institution projects must also include a plan for single-IRB arrangements. Similarly, animal studies require review by both the local IACUC and the USAMRDC Animal Care and Use Review Office (ACURO), with an expected 3 to 4 months for ACURO review. If projects rely on DoD or VA populations, databases, or resources, the application must explain access plans up front and how that access will be maintained throughout the project.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Translational Science Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 05, 2021.
• Applicants must submit their applications by Jul 29, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PCRP TSA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: